Recently, mainland China’s chain ophthalmology medical company “Aier Ophthalmology” issued a tax supplement announcement, stating that the company needs to make up a total of 524 million yuan in taxes and overdue fines. Following the release of this news, the company’s A-share stock price plummeted, causing a market value loss of approximately 3.8 billion yuan in just one day.
Aier Ophthalmology announced on May 20 that, after self-examination, the company needed to make up 348 million yuan in taxes and 176 million yuan in overdue fines, totaling 524 million yuan. As of the date of the announcement, the aforementioned taxes and fines have been fully paid.
According to the announcement, the company needs to increase the 2025 annual corporate income tax settlement and payment declaration amount by 232 million yuan; the related impact will be reflected in the 2026 current income statement, without affecting retrospective adjustments to previous financial data or normal operations.
Reported by “Sina Finance” on May 20, Aier Ophthalmology’s stock price dropped on the day of the tax supplement announcement. As of the closing of A-shares on May 20, Aier Ophthalmology was trading at 9.47 yuan per share, a decrease of 4.15%, with a total market value of approximately 88.3 billion yuan, evaporating around 3.8 billion yuan from the previous trading day.
“Yicai” reported on May 20 that the financial report showed Aier Ophthalmology achieved operating income of 22.353 billion yuan in 2025, a year-on-year increase of 6.53%; the net profit attributable to the shareholders of the listed company was 3.24 billion yuan, a year-on-year decrease of 8.88%, marking the first annual decline in net profit since the company went public. In terms of business segments, apart from a 10.26% increase in revenue from refractive items, the revenue growth of major items such as cataracts and anterior segment were all lower than 10%.
This tax supplement incident occurred during Aier Ophthalmology’s preparation for listing in Hong Kong. Public information shows that the company’s board of directors approved the proposal to issue H shares and list on the main board of the Hong Kong Stock Exchange on April 23; on May 18, the proposal was approved by the shareholders’ meeting, with the validity period set at 24 months from the date of approval.
Mainland media reports indicate that the funds raised for Aier Ophthalmology’s upcoming listing in Hong Kong will be used for hospital expansion, mergers and acquisitions, AI and research and development, as well as replenishing working capital.
Public data shows that Aier Ophthalmology was established in 2002 and went public on the ChiNext board of the Shenzhen Stock Exchange in 2009, primarily engaging in ophthalmic diagnosis, surgical services, and medical optometry services. The company’s medical institutions are located in mainland China and some overseas regions.
Previously reported by Epoch Times, several hospitals under Aier Ophthalmology have been penalized for violations related to the use of medical insurance funds, price fraud, qualifications of practicing doctors, damaged surgical instruments, and advertising irregularities. Furthermore, several Aier Ophthalmology hospitals have been involved in medical malpractice liability disputes.
In recent disclosure of tax supplement matters by A-share companies, not only Aier Ophthalmology is impacted, as multiple companies have had to make billion-yuan level supplements.
According to mainland China’s financial information website “Finance News,” citing incomplete data from “Tonghuashun iFinD,” since May, eight listed companies including Aier Ophthalmology, Yunnan Copper, Jingneng Thermal Power, Hefeng Shares, Langwei Shares, Taiji Industrial, Enjie Shares, and Huabang Health have disclosed news related to tax payment supplements.